Comparison 3. A. Anti‐pseudomonal penicillins: piperacillin‐tazobactam vs imipenem‐cilastatin.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinical resolution of the infection	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	1.66 [0.84, 3.26]
2 Adverse effects	1	320	Risk Ratio (M‐H, Fixed, 95% CI)	3.50 [1.56, 7.86]
2.1 Any adverse event	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	3.19 [0.95, 10.72]
2.2 Hepatotoxicity	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	5.32 [0.66, 43.05]
2.3 Nephrotoxicity	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	6.39 [0.81, 50.09]
2.4 Hematological side effects	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	5.31 [0.27, 106.46]
2.5 Nausea	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	0.35 [0.01, 8.38]
3 Amputations	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	0.87 [0.59, 1.28]
4 Recurrence	1	64	Risk Ratio (M‐H, Fixed, 95% CI)	5.31 [0.27, 106.46]